ArticleArchives of medical science : AMS2025
Updated focused review of hematological, inflammatory, and lipid biomarkers in acute coronary syndrome.
Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neutrophil-to-HDL-C Ratio and Anatomically Significant Multivessel Disease Across Acute Coronary Syndrome Phenotypes.Medeniyet medical journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At present, hematological indices and biomarkers of inflammation that may be associated with atherosclerosis and the prediction of acute coronary syndromes (ACS) attract a lot of academic attention. This updated focused review aims to provide an overview of selected ACS biomarkers: white blood cells, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, systemic inflammatory index (SII), systemic inflammatory response index (SIRI) and lipoprotein(a). Novel inflammatory-lipid biomarkers such as high-sensitivity C-reactive protein (hsCRP) to high-density lipoprotein cholesterol (HDL-C) ratio, neutrophil to HDL-C ratio, and monocyte to HDL-C ratio may improve ACS diagnosis, risk stratification, clinical prognosis, and optimal management. These indices are inexpensive and easily obtained in daily clinical practice. Artificial intelligence and genetic analysis may improve their diagnostic performance and guide clinical management. The recent data also emphasize that these indices may be promising clinical tools for assessing ACS patients and monitoring the effectiveness of emerging anti-inflammatory strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.